Related Experiment Video
Updated: Sep 14, 2025

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
Head and Neck Cancer in Southeast Asia: 2022 Incidence, Mortality, and Projections to 2050
Jenny Chen1, Aryan Selokar2, Frances Dominique V Ho3
1Department of Surgery, Division of Plastic and Reconstructive Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Objectives:
To characterize the incidence, mortality, and disparities in head and neck cancer (HNC) across Southeast Asia (SEA) in 2022 and project trends to 2050 to inform cancer planning.
Methods:
We conducted a population-based analysis using 2022 Global Cancer Observatory data from 11 SEA countries. We analyzed cancers of the lip and oral cavity, salivary glands, oropharynx, nasopharynx, hypopharynx, larynx, and thyroid. Age-standardized incidence and mortality rates (ASIR and ASMR) were calculated using the Segi-Doll world standard. Projections to 2050 were based on demographic changes using UN World Population Prospects data, assuming stable incidence and mortality rates.
Results:
Myanmar had the highest oral cancer rates (ASIR: 6.6 males, 2.6 females; ASMR: 3.9 males, 1.6 females). Elevated salivary gland cancer incidence was observed in Indonesia, the Philippines, and Singapore. Oropharyngeal cancers showed strong male predominance in Myanmar (ASIR ratio: 10:1). Nasopharyngeal cancer incidence in Brunei and Indonesia exceeded global averages (ASIR: 9.8 and 9.6 males). Projections to 2050 estimate 47,000 new male cases and 28,200 new female cases in Indonesia, with 30,600 male deaths and 12,200 female deaths. While SEA's overall ASIR for HNC (18.0) was comparable to the global average (18.9), the ASMR was significantly higher (9.5 vs. 5.3).
Conclusions:
The rising burden of HNC in SEA highlights urgent disparities in incidence and mortality. Targeted prevention, early detection, and investment in cancer care systems are essential to mitigate future disease burden and improve outcomes.
Level Of Evidence:
Level III-Epidemiologic study using population-based registry data.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Related Concept Videos
Cancer Survival Analysis
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Cancer Prevention
Some...